National Cell Therapy Facility at HSA

A new funding initiative for RIE2020, the National Cell Therapy Facility serves as a neutral, Good Manufacturing Practice (GMP) certified, public sector wide infrastructure asset available to medical professionals and scientific researchers from public sector healthcare and academic research centres.  The facility is established to be the national research and translational service for manufacturing and production of high quality cell therapy products for safe and affordable administration to patients, under the International Good Manufacturing Practice (GMP PIC/S) standards. This will serve as an enabler of research while providing the infrastructure, scientific know-how and technical expertise needed to support the evolving field of cell therapy, together with its potential health and economic benefits. 

Please click here for more information.

Last updated: 9 May 2018